Obicetrapib
A potent CETP inhibitor from Mitsubishi Tanabe Pharma that lowers LDL by 50% on top of statins and dramatically increases HDL, showing promise for various diseases including Alzheimer's, septicemia, and diabetes.
Save the 2 videos on Obicetrapib to your own pod.
Sign up free to keep building your knowledge base on Obicetrapib as more episodes are added.
Videos Mentioning Obicetrapib
255-Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease, familial hypercholesterolemia
Peter Attia MD
A potent CETP inhibitor from Mitsubishi Tanabe Pharma that lowers LDL by 50% on top of statins and dramatically increases HDL, showing promise for various diseases including Alzheimer's, septicemia, and diabetes.
395 – Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer’s disease, & more
Peter Attia MD
A recent CETP inhibitor primarily aimed at reducing ApoB and major adverse cardiovascular events (MACE). Early data from the Broadway trial suggests it favorably impacts Alzheimer's biomarkers, potentially by increasing APOA1 and protective HDL species in the brain.